Subscribe
JPMorgan鈥檚 analysis suggests that while prospects have improved, valuations have yet to respond
The company has upgraded guidance twice this year, but still trades as a value share
Simon Thompson: Earnings are upgraded 19 per cent and the shares trade 36 per cent below NAV
Simon Thompson: Shares trade 40 per cent below NAV even though the fund is exposed to rampant precious metals
Cost cuts offset the damage of another year of falling sales
Simon Thompson: A stream of case losses has led to a huge loss and sharply higher debt
The asthma and COPD testing specialist looks operationally solid in the wake of failed talks
Asian oil and gas is popular with investors more broadly, but the company has fumbled any momentum
The animal medicines specialist looks to secure its future by increasing R&D spending
Excluding the crisis-hit agency, the wider group held margins steady despite softer revenues
